Expert Interview
A Second Look: Discussing Reata's SKYCLARYS (omaveloxolone) post FDA approval and the potential for competing Friedreich's Ataxia therapies
Ticker(s): RETAInstitution: SUNY Downstate Medical Center
- Director of the Muscular Dystrophy Association Clinic and Associate Professor of Neurology at SUNY Downstate Medical Center.
- Treats 8 patients with ATTR-PN, 15 patients for Friedreich’s Ataxia and 90 patients with myasthenia gravis.
- Research Interests in HIV-related neuropathy, inflammatory myopathies and has a clinical specialty in Neuromuscular disease.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
